Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

) of patients continuing past 24 weeks in this study achieved the ADA target A1C goal of less than seven percent on JANUVIA 50 mg/metformin 1000 mg twice daily (n=153) compared to 44 percent on metformin 1000 mg twice daily alone (n=134). Further, 48 percent of patients treated with JANUVIA 50 mg/metformin 500 mg twice daily (n=147), 25 percent of patients treated with metformin 500 mg twice daily (n=117), and 23 percent of patients treated with JANUVIA 100 mg once daily (n=106) reached the ADA target A1C goal.

Duration of response was demonstrated by data showing that 85 percent of patients treated with JANUVIA 50 mg/metformin 1000 mg twice daily and 70 percent of patients treated with JANUVIA 100 mg once daily who achieved the target A1C goal of less than seven percent at Week 24 had a Week 54 A1C value of less than seven percent (n=96 and 33, respectively). In addition, 80 percent of patients treated with JANUVIA 50 mg/metformin 500 mg twice daily (n=65), 79 percent of patients treated with metformin 1000 mg twice daily (n=63), and 59 percent of patients treated with metformin 500 mg twice daily (n=34) who reached a goal A1C of less than seven percent at Week 24 had a Week 54 A1C value of less than seven percent.

Over the 54 week study, five out of 182 patients (three percent) treated with JANUVIA 50 mg/metformin 1000 mg twice daily and two out of 182 patients (one percent) treated with metformin 1000 mg twice daily had at least one episode of hypoglycemia. Incidences of gastrointestinal adverse experiences were similar to those observed with metformin alone (26 percent vs. 31 percent with metformin 1000 mg twice daily).

"Initial therapy with one agent is often unsuccessful at getting patients to blood sugar goals. Many patients may require initial combination therapy, and this study provides important and useful information about the use of sitagliptin and metformin, in addition to diet and exercise, in order to achieve and maintain blood su
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)... is pleased to announce the appointment of Dr. ... Biochemistry. Scott joins the company after previous scientific leadership positions ... course of his nearly 20 year career in therapeutics ... recognized thought leader in the biosensor field and particularly ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... focus on Omega-3 therapies for cardiovascular disease and overall health ... Company,s accomplishments in 2014 and its outlook for 2015 from ... Fellow Shareholders, We would like to take this ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... OrbusNeich announced that data from multiple clinical trials supporting ... cases where prolonged dual antiplatelet therapy (DAPT) is not ... "How to assess and treat patients who are not ... 2011 in Paris. Presenters discussed current treatment ...
... LAKE CITY, May 19, 2011 Paradigm Medical Industries, ... notification from its Italian partner, Costruzione Strumenti Oftalmici (CSO), ... pages and 24 attachments to the U.S. Food and ... for the Paramax™. This supportive information was submitted to ...
Cached Medicine Technology:OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 2OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 3OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 4Paramax™ Moves Closer To FDA Approval 2
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... exercise daily can improve mood and reduce fatigue, study reports. ... towars the physical asset. But as far as mental fatigue is ... benefit. This is based on the preliminary findings which included 14 ... not find any benefits as far as mood is concerned. ...
... in the recent issue of the American Journal of ... against a hip fracture. According to Dr. Susanne Hoidrup ... people undergo the aging process, regular physical activity should ... to control the alarming increase in hip fractures. ...
... are far more likely to miscarrry after IVF treatment- but ... say doctors. ,They are urging overweight women to change ... treatments. ,Obese women have long been known to have ... success rates for IVF do not match those of those ...
... Drug Administration (FDA) at a conference in Washington, approves the ... the sign of a protein known to cause cancer. It ... leukemia (CML). Other molecular-targeting drugs previously approved by ... but not with proteins that directly cause the disease. ...
... form of epidemic fevers, is spread by a virulent ... ,"We have 12 deaths (in the past fortnight) from ... in city hospitals, " Maharashtra state Health Minister Digvijay ... is being misdiagnosed by majority of the private doctors ...
... with the help of fertility treatment grow into emotionally ... ,The world's first study that followed in-vitro, or test ... youngsters who had been conceived through fertility treatments do ... ,Since Louise Brown, the world's first test tube ...
Cached Medicine News:
Set of 5 large bone curettes. One each of the following: angled small, straight small, angled medium, straight medium, and angled large....
Custom-made chisels....
Reduction Forceps with Points for precise reduction of bone fragments with minimal soft tissue contact....
Straight double action bone cutting rongeur....
Medicine Products: